BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 22709792)

  • 1. Novel targeted agents for gastric cancer.
    Liu L; Wu N; Li J
    J Hematol Oncol; 2012 Jun; 5():31. PubMed ID: 22709792
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted therapy for gastric cancer: Current status and future directions (Review).
    Yuan DD; Zhu ZX; Zhang X; Liu J
    Oncol Rep; 2016 Mar; 35(3):1245-54. PubMed ID: 26718131
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Perspectives of the stomach cancer treatment: the introduction of molecular targeted therapy and the hope for cure].
    Cheung DY; Kim JK
    Korean J Gastroenterol; 2013 Mar; 61(3):117-27. PubMed ID: 23575230
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular targeting to treat gastric cancer.
    Aoyagi K; Kouhuji K; Kizaki J; Isobe T; Hashimoto K; Shirouzu K
    World J Gastroenterol; 2014 Oct; 20(38):13741-55. PubMed ID: 25320512
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advanced HER2-positive gastric cancer: current and future targeted therapies.
    Pazo Cid RA; Antón A
    Crit Rev Oncol Hematol; 2013 Mar; 85(3):350-62. PubMed ID: 23021388
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent advances and future trends in the targeted therapy of metastatic gastric cancer.
    Al-Batran SE; Werner D
    Expert Rev Gastroenterol Hepatol; 2014 Jul; 8(5):555-69. PubMed ID: 24665840
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent updates of precision therapy for gastric cancer: Towards optimal tailored management.
    Joo MK; Park JJ; Chun HJ
    World J Gastroenterol; 2016 May; 22(19):4638-50. PubMed ID: 27217696
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted therapy in advanced gastric carcinoma: the future is beginning.
    Schinzari G; Cassano A; Orlandi A; Basso M; Barone C
    Curr Med Chem; 2014; 21(8):1026-38. PubMed ID: 24304282
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical management of advanced gastric cancer: the role of new molecular drugs.
    De Vita F; Di Martino N; Fabozzi A; Laterza MM; Ventriglia J; Savastano B; Petrillo A; Gambardella V; Sforza V; Marano L; Auricchio A; Galizia G; Ciardiello F; Orditura M
    World J Gastroenterol; 2014 Oct; 20(40):14537-58. PubMed ID: 25356019
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Predictive diagnosis of HER2 in gastric adenocarcinoma].
    Daum O; Skálová A; Rozkos T; Laco J
    Cesk Patol; 2011 Oct; 47(4):160-3. PubMed ID: 22145214
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Molecular targeting agents for advanced or recurrent gastric cancer patients].
    Fuse N
    Nihon Rinsho; 2012 Oct; 70(10):1819-26. PubMed ID: 23198568
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gastric Carcinoma at the Era of Targeted Therapies.
    Dreanic J; Dhooge M; Sion E; Brezault C; Chaussade S; Coriat R
    Curr Drug Targets; 2016; 17(15):1818-1826. PubMed ID: 25944013
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Challenges in molecular targeted therapy for gastric cancer: considerations for efficacy and safety.
    Narita Y; Muro K
    Expert Opin Drug Saf; 2017 Mar; 16(3):319-327. PubMed ID: 27976952
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted therapy for gastric cancer.
    Smyth EC; Cunningham D
    Curr Treat Options Oncol; 2012 Sep; 13(3):377-89. PubMed ID: 22552927
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current advances in targeted therapies for metastatic gastric cancer: improving patient care.
    Aguiar PN; Muniz TP; Miranda RR; Tadokoro H; Forones NM; Monteiro ID; Castelo-Branco P; Janjigian YY; De Mello RA
    Future Oncol; 2016 Mar; 12(6):839-54. PubMed ID: 26838766
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Personalized medicine in gastric cancer: Where are we and where are we going?
    Jácome AA; Coutinho AK; Lima EM; Andrade AC; Dos Santos JS
    World J Gastroenterol; 2016 Jan; 22(3):1160-71. PubMed ID: 26811654
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of the antitumor effects and mechanisms of PF00299804, a pan-HER inhibitor, alone or in combination with chemotherapy or targeted agents in gastric cancer.
    Nam HJ; Ching KA; Kan J; Kim HP; Han SW; Im SA; Kim TY; Christensen JG; Oh DY; Bang YJ
    Mol Cancer Ther; 2012 Feb; 11(2):439-51. PubMed ID: 22135232
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of different molecular targeted agents based on chemotherapy for gastric cancer patients treatment: a network meta-analysis.
    Ren Z; Sun J; Sun X; Hou H; Li K; Ge Q
    Oncotarget; 2017 Jul; 8(29):48253-48262. PubMed ID: 28477027
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted therapy for advanced esophagogastric adenocarcinoma.
    Kordes S; Cats A; Meijer SL; van Laarhoven HW
    Crit Rev Oncol Hematol; 2014 Apr; 90(1):68-76. PubMed ID: 24183912
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeted therapy in gastric cancer.
    Thiel A; Ristimäki A
    APMIS; 2015 May; 123(5):365-72. PubMed ID: 25706252
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.